At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat.

Artificial intelligence specialist Artera has won FDA approval for AI-powered software that can help guide the management of patients diagnosed with localised prostate cancer. ArteraAI Prostate is ...

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

HHS Secretary Kennedy adds yet another layer of scrutiny to childhood vaccines with the re-establishment of a task force disbanded in the 1990s.